pre-IPO PHARMA

COMPANY OVERVIEW

Korro Bio was created to lead the field of RNA editing. The company is advancing a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. Korro Bio was established in 2018 by Atlas Venture.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS


    WEBSITE

    https://www.korrobio.com


    CAREER WEBSITE

    https://www.korrobio.com/#careers


    SOCIAL MEDIA


    INVESTORS

    atlas-venture nea


    PRESS RELEASES


    Jul 14, 2023

    Korro Bio and Frequency Therapeutics Announce Merger Agreement


    Mar 7, 2023

    Korro Bio and Genevant Sciences Enter into Collaboration Agreement to Develop RNA Editing Therapeutic for Alpha-1 Antitrypsin Deficiency


    Feb 28, 2023

    Korro Bio Appoints Dr. Steve Colletti as Chief Scientific Officer


    Jan 4, 2023

    Korro Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference


    Nov 8, 2022

    Korro Bio Expands Leadership Team with Key Appointments


    For More Press Releases


    Google Analytics Alternative